CL
CL.CD
—
—
Personal Products
Cresco Labs Inc.
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-6,9 %
ROE
-39,8 %
Net margin
-20,6 %
Debt / equity
1,32
Beta
—
52w range
—
Volume
25,3k
Day range
$89,17–$91,81
Prev close
$89,88
Open
$89,17
Next earnings
2026-10-28
Ex-dividend
—
TR 1Y
—
About
The company operates in the pharmaceuticals industry, developing and commercializing prescription drugs, with a focus on innovative therapies for chronic and complex diseases.
Business. CL.CD is a pharmaceutical company operating within the Healthcare sector, specifically engaged in the Pharmaceuticals industry. The firm generates revenue through the sale of pharmaceutical products. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
Classification99 %
SectorConsumer Staples
Industry groupPersonal Products
Generated · model-assisted
Sell-side consensus
BUY8 analysts
8 buy0 hold0 sell
Avg 12m price target2,22
Analyst recommendations
8 analysts · consensus BuyBuy8
Hold0
Sell0
12-month price target
2,22
Consensus of sell-side coverage.
At a glance
Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
8 analysts · indicative
Ownership→
EATON VANCE MANAGEMENT
largest disclosed fund holder
Profitability→
-39,8 %
return on equity
Quality
—
not yet scored
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
— missing data
News & coverage
0Sector rotation
Sector1D1Mvs mkt
Materials+2,3 %+6,6 %+1,7 %
Communication Services+2,2 %−5,5 %+1,6 %
Energy+0,6 %+3,3 %+0,0 %
Health Care+0,6 %−0,8 %+0,0 %
Information Technology+0,6 %+6,7 %+0,0 %
Consumer Discretionary+0,4 %+7,6 %−0,2 %
Financials−0,3 %−2,8 %−0,9 %
Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
Real Estate−0,7 %+10,9 %−1,3 %
Industrials−1,9 %−3,1 %−2,5 %
Utilities−1,9 %+28,2 %−2,5 %
Developing storylines
No tracked sagas currently linked to CL.CD. Browse all sagas →
Analysis
AI analysis
Generated · analysis pipeline · tier hybrid · as of 2026-08-04
↑ At a glance
Opportunity
— missing data
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
- Congressional trades
- CongressJulie Johnson — Colgate-Palmolive Company Common2025-09-25 · Democrat · TX · Sale · $1,001 - $15,000
- CongressLisa McClain — Colgate-Palmolive Company Common2025-09-11 · Republican · MI · Sale · $1,001 - $15,000
- CongressLisa McClain — Colgate-Palmolive Company Common2025-08-13 · Republican · MI · Purchase · $1,001 - $15,000
- CongressLisa McClain — Colgate-Palmolive Company Common2025-06-24 · Republican · MI · Sale · $1,001 - $15,000
- CongressLisa McClain — Colgate-Palmolive Company Common2025-06-17 · Republican · MI · Purchase · $1,001 - $15,000
- CongressCindy Axne — Colgate-Palmolive Company2019-12-31 · IA · Purchase · $1,001 - $15,000
Pre-earnings brief
— missing data
Signals & dispatch
peak dispatch · —
Composite-score breakdown
Synthesis
Business
CL.CD is a pharmaceutical company operating within the Healthcare sector, specifically engaged in the Pharmaceuticals industry. The firm generates revenue through the sale of pharmaceutical products. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.
Classification99 %
SectorConsumer Staples
Industry groupPersonal Products
AI synthesis
GENERATEDThe company's capital structure is characterized by a debt-to-equity ratio of 1.32, indicating a moderate reliance on debt financing. Its liquidity position is mixed, with $57.9 million in cash and equivalents, but a negative free cash flow of $128.7 million and a net loss of $135.4 million. The current ratio of 2.59 suggests the company can cover its short-term liabilities, but the negative operating income of $45.5 million raises concerns about its ability to sustain operations without external financing.
Profitability metrics are weak, with a return on equity of -39.77% and a return on assets of -11.31%. These figures fall significantly below the industry median for pharmaceutical companies, which typically exhibit positive returns due to high-margin product portfolios. The company's operating margin is negative, and its net loss indicates a failure to convert revenue into profit, which is a red flag in a capital-intensive industry.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, such as regulatory changes or reimbursement pressures in key markets. The absence of segment or geographic breakdown in the financial data limits the ability to assess the resilience of different parts of the business.
The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent period. Analysts have assigned a mean price target of $2.22, with a median of $2.25, but no strong buy recommendations. The company's operating cash flow of $36.5 million is insufficient to cover capital expenditures of $38.2 million, suggesting a need for external financing to fund operations and growth initiatives.
Risk factors include a negative net cash position after subtracting total debt, which increases liquidity risk. The company's diluted share count is unchanged from the basic share count, indicating no near-term dilution pressure. However, the negative free cash flow and operating income suggest a potential need for equity or debt financing in the near future, which could introduce dilution risk.
Recent events include the publication of the latest financial results, which show a significant decline in profitability. No recent filings or transcripts have been disclosed that provide additional insight into the company's strategic direction or operational performance. The absence of recent guidance or commentary from management limits the ability to assess the company's response to market challenges.
Key takeaways
- The company is operating at a net loss with negative returns on equity and assets, indicating poor profitability.
- The debt-to-equity ratio of 1.32 suggests a moderate reliance on debt, but the negative free cash flow raises concerns about liquidity.
- The company's revenue is concentrated in a single segment, with no geographic diversification disclosed, increasing exposure to market-specific risks.
- Analysts have assigned a mean price target of $2.22, but no strong buy recommendations, reflecting cautious sentiment.
- The company's operating cash flow is insufficient to cover capital expenditures, suggesting a need for external financing.
Bull / Bear case
Generated · model-assisted— missing data
In focus — financials by report
Valuation
Market price
$1,12
Market cap
—
Enterprise valueⓘ
—
P/Eⓘ
—
Non-GAAP P/Eⓘ
—
EV / Revenueⓘ
—
EV / Op incomeⓘ
—
EV / OCFⓘ
—
P / Bⓘ
—
P / Tangible bookⓘ
—
Tangible book
$340.4M
Net cashⓘ
-$390.7M
Current ratioⓘ
2.6
Debt / equityⓘ
1.3
ROAⓘ
-11.3%
ROEⓘ
-39.8%
Cash conversionⓘ
-27.0%
CapEx / revenueⓘ
-5.8%
SBC / revenueⓘ
—
Dilution ratioⓘ
0.0%
Revenue by segment
Business relationships
Business relationships227 disclosed relationships · 2 types · extracted from filings & disclosures
Customers1
Walmart IncWMT.OCustomer88%Source ↗
Subsidiaries226
EX21:0016d5698f38EX21:0016d5698f38Subsidiarie97%
EX21:0154a40adbfcEX21:0154a40adbfcSubsidiarie97%
EX21:0256b2baf08dEX21:0256b2baf08dSubsidiarie97%
EX21:026dfe9c004aEX21:026dfe9c004aSubsidiarie97%
EX21:02d6d62284fcEX21:02d6d62284fcSubsidiarie97%
EX21:037068adc38fEX21:037068adc38fSubsidiarie97%
EX21:03d04f7fcebcEX21:03d04f7fcebcSubsidiarie97%
EX21:0421f609ecc5EX21:0421f609ecc5Subsidiarie97%
EX21:0480d0d3bfe9EX21:0480d0d3bfe9Subsidiarie97%
EX21:04f0b1f2329aEX21:04f0b1f2329aSubsidiarie97%
EX21:05899cf82081EX21:05899cf82081Subsidiarie97%
EX21:0610e7f9a1b6EX21:0610e7f9a1b6Subsidiarie97%
EX21:0667837ad4aeEX21:0667837ad4aeSubsidiarie97%
EX21:0700763055b1EX21:0700763055b1Subsidiarie97%
EX21:07f064a47dc5EX21:07f064a47dc5Subsidiarie97%
EX21:0832b8301cfaEX21:0832b8301cfaSubsidiarie97%
EX21:08ff3b07f000EX21:08ff3b07f000Subsidiarie97%
EX21:0950bac41b81EX21:0950bac41b81Subsidiarie97%
EX21:09cd67084549EX21:09cd67084549Subsidiarie97%
EX21:0ace48057caaEX21:0ace48057caaSubsidiarie97%
EX21:0c605f333e7dEX21:0c605f333e7dSubsidiarie97%
EX21:0cdb79236a61EX21:0cdb79236a61Subsidiarie97%
EX21:0d00990df261EX21:0d00990df261Subsidiarie97%
EX21:0d05f2fb5464EX21:0d05f2fb5464Subsidiarie97%
EX21:0ebf43dc889aEX21:0ebf43dc889aSubsidiarie97%
EX21:11826aeb74b2EX21:11826aeb74b2Subsidiarie97%
EX21:12758bf134feEX21:12758bf134feSubsidiarie97%
EX21:12847c73c1f5EX21:12847c73c1f5Subsidiarie97%
EX21:12c97fd7bf45EX21:12c97fd7bf45Subsidiarie97%
EX21:13ca22efe69cEX21:13ca22efe69cSubsidiarie97%
EX21:16511a46ab92EX21:16511a46ab92Subsidiarie97%
EX21:16611c9a5329EX21:16611c9a5329Subsidiarie97%
EX21:16c831c9341eEX21:16c831c9341eSubsidiarie97%
EX21:16cbf8e4aa22EX21:16cbf8e4aa22Subsidiarie97%
EX21:18bb62ff8f24EX21:18bb62ff8f24Subsidiarie97%
EX21:1a6ab302267aEX21:1a6ab302267aSubsidiarie97%
EX21:1a87dc699d0bEX21:1a87dc699d0bSubsidiarie97%
EX21:1bd038bd933aEX21:1bd038bd933aSubsidiarie97%
EX21:1c5865bbf54fEX21:1c5865bbf54fSubsidiarie97%
EX21:1d1f009aa5a9EX21:1d1f009aa5a9Subsidiarie97%
EX21:1d6f04082876EX21:1d6f04082876Subsidiarie97%
EX21:1ecb2990b724EX21:1ecb2990b724Subsidiarie97%
EX21:204cec9cb393EX21:204cec9cb393Subsidiarie97%
EX21:2110d7117afeEX21:2110d7117afeSubsidiarie97%
EX21:214e34efbef1EX21:214e34efbef1Subsidiarie97%
EX21:251b34acbab2EX21:251b34acbab2Subsidiarie97%
EX21:255fbf4f3eb8EX21:255fbf4f3eb8Subsidiarie97%
EX21:25d1b21644f1EX21:25d1b21644f1Subsidiarie97%
EX21:26f994fb3cabEX21:26f994fb3cabSubsidiarie97%
EX21:2764badd319bEX21:2764badd319bSubsidiarie97%
EX21:27920d761e95EX21:27920d761e95Subsidiarie97%
EX21:2ab9543b1073EX21:2ab9543b1073Subsidiarie97%
EX21:2ad71dd639e7EX21:2ad71dd639e7Subsidiarie97%
EX21:2b8aec9674a7EX21:2b8aec9674a7Subsidiarie97%
EX21:2c6b1745c600EX21:2c6b1745c600Subsidiarie97%
EX21:2f75b63cf6bdEX21:2f75b63cf6bdSubsidiarie97%
EX21:3040d10784a1EX21:3040d10784a1Subsidiarie97%
EX21:3499b158f22cEX21:3499b158f22cSubsidiarie97%
EX21:34d50c186276EX21:34d50c186276Subsidiarie97%
EX21:34df4602b979EX21:34df4602b979Subsidiarie97%
EX21:35900bdec3a5EX21:35900bdec3a5Subsidiarie97%
EX21:36831779968bEX21:36831779968bSubsidiarie97%
EX21:368f9e0251dfEX21:368f9e0251dfSubsidiarie97%
EX21:37ac29eabbfcEX21:37ac29eabbfcSubsidiarie97%
EX21:3a0e5c34f816EX21:3a0e5c34f816Subsidiarie97%
EX21:3ac4a2cbab04EX21:3ac4a2cbab04Subsidiarie97%
EX21:3d6b5a40afa4EX21:3d6b5a40afa4Subsidiarie97%
EX21:3d827ef894acEX21:3d827ef894acSubsidiarie97%
EX21:3df35a1aa736EX21:3df35a1aa736Subsidiarie97%
EX21:3f7d3a384b49EX21:3f7d3a384b49Subsidiarie97%
EX21:3fe06c04c2c0EX21:3fe06c04c2c0Subsidiarie97%
EX21:40ff19f8b0dfEX21:40ff19f8b0dfSubsidiarie97%
EX21:4266dd769610EX21:4266dd769610Subsidiarie97%
EX21:45d409ccfd91EX21:45d409ccfd91Subsidiarie97%
EX21:4643f80bed1aEX21:4643f80bed1aSubsidiarie97%
EX21:4b852d24cd06EX21:4b852d24cd06Subsidiarie97%
EX21:5163e06708abEX21:5163e06708abSubsidiarie97%
EX21:51dcf45a1512EX21:51dcf45a1512Subsidiarie97%
EX21:5243d9eee8a2EX21:5243d9eee8a2Subsidiarie97%
EX21:5293a2bad1b9EX21:5293a2bad1b9Subsidiarie97%
EX21:537f99308902EX21:537f99308902Subsidiarie97%
EX21:53b4ac39d278EX21:53b4ac39d278Subsidiarie97%
EX21:570879fd9f6dEX21:570879fd9f6dSubsidiarie97%
EX21:58d1f0580ee2EX21:58d1f0580ee2Subsidiarie97%
EX21:5d0de66a260eEX21:5d0de66a260eSubsidiarie97%
EX21:5db0b3eb2bc8EX21:5db0b3eb2bc8Subsidiarie97%
EX21:5edcd040363fEX21:5edcd040363fSubsidiarie97%
EX21:5ff72c38f898EX21:5ff72c38f898Subsidiarie97%
EX21:6007b44327a4EX21:6007b44327a4Subsidiarie97%
EX21:622b82680199EX21:622b82680199Subsidiarie97%
EX21:6345f9eae75dEX21:6345f9eae75dSubsidiarie97%
EX21:65b6d4d96f03EX21:65b6d4d96f03Subsidiarie97%
EX21:6604ae71b99bEX21:6604ae71b99bSubsidiarie97%
EX21:6614ba99c706EX21:6614ba99c706Subsidiarie97%
EX21:67f98db1bbc6EX21:67f98db1bbc6Subsidiarie97%
EX21:68678bd1677dEX21:68678bd1677dSubsidiarie97%
EX21:68ad5318b503EX21:68ad5318b503Subsidiarie97%
EX21:68f1b50c4e8eEX21:68f1b50c4e8eSubsidiarie97%
EX21:69cc86ee3475EX21:69cc86ee3475Subsidiarie97%
EX21:6a7a0d3fa3dbEX21:6a7a0d3fa3dbSubsidiarie97%
EX21:6bd9888bf307EX21:6bd9888bf307Subsidiarie97%
EX21:6c6c647434c5EX21:6c6c647434c5Subsidiarie97%
EX21:6d498b6e2de3EX21:6d498b6e2de3Subsidiarie97%
EX21:6dc4c1668c50EX21:6dc4c1668c50Subsidiarie97%
EX21:6de849a51077EX21:6de849a51077Subsidiarie97%
EX21:6e02bd2d71d9EX21:6e02bd2d71d9Subsidiarie97%
EX21:6e1cbce9640aEX21:6e1cbce9640aSubsidiarie97%
EX21:6e1d0ce37168EX21:6e1d0ce37168Subsidiarie97%
EX21:6eba5a0dc33cEX21:6eba5a0dc33cSubsidiarie97%
EX21:70a7135562b6EX21:70a7135562b6Subsidiarie97%
EX21:70e85054fb54EX21:70e85054fb54Subsidiarie97%
EX21:71f9818644c5EX21:71f9818644c5Subsidiarie97%
EX21:72cec2eb34aeEX21:72cec2eb34aeSubsidiarie97%
EX21:73502dbae4e6EX21:73502dbae4e6Subsidiarie97%
EX21:7385c57d3d05EX21:7385c57d3d05Subsidiarie97%
EX21:7628093f40b8EX21:7628093f40b8Subsidiarie97%
EX21:7691651dcad3EX21:7691651dcad3Subsidiarie97%
EX21:76d9c30e1d05EX21:76d9c30e1d05Subsidiarie97%
EX21:77904f6ddcc2EX21:77904f6ddcc2Subsidiarie97%
EX21:77a2d7891f74EX21:77a2d7891f74Subsidiarie97%
EX21:79b171f8914dEX21:79b171f8914dSubsidiarie97%
EX21:7bef2dd8d034EX21:7bef2dd8d034Subsidiarie97%
EX21:7d99d652a975EX21:7d99d652a975Subsidiarie97%
EX21:7e1710c6b695EX21:7e1710c6b695Subsidiarie97%
EX21:7f2879b9cb72EX21:7f2879b9cb72Subsidiarie97%
EX21:8124937c5352EX21:8124937c5352Subsidiarie97%
EX21:836849a6ebbbEX21:836849a6ebbbSubsidiarie97%
EX21:86bb5da1ab66EX21:86bb5da1ab66Subsidiarie97%
EX21:87cdd1457b79EX21:87cdd1457b79Subsidiarie97%
EX21:87e4875edbf0EX21:87e4875edbf0Subsidiarie97%
EX21:88a9d34befedEX21:88a9d34befedSubsidiarie97%
EX21:89ae580afa49EX21:89ae580afa49Subsidiarie97%
EX21:8b368855ba46EX21:8b368855ba46Subsidiarie97%
EX21:8bc85f473e2eEX21:8bc85f473e2eSubsidiarie97%
EX21:90056182eb6aEX21:90056182eb6aSubsidiarie97%
EX21:90c4bde3753eEX21:90c4bde3753eSubsidiarie97%
EX21:916e1a80606fEX21:916e1a80606fSubsidiarie97%
EX21:924304ecd963EX21:924304ecd963Subsidiarie97%
EX21:92e94f13712eEX21:92e94f13712eSubsidiarie97%
EX21:9518a01b4936EX21:9518a01b4936Subsidiarie97%
EX21:962ec8abeba2EX21:962ec8abeba2Subsidiarie97%
EX21:97075cb29726EX21:97075cb29726Subsidiarie97%
EX21:9731ce71eabeEX21:9731ce71eabeSubsidiarie97%
EX21:9764777b0e6dEX21:9764777b0e6dSubsidiarie97%
EX21:98f9587782cfEX21:98f9587782cfSubsidiarie97%
EX21:99b2ef8ec8a4EX21:99b2ef8ec8a4Subsidiarie97%
EX21:99f35d89574fEX21:99f35d89574fSubsidiarie97%
EX21:9a0d88fcf472EX21:9a0d88fcf472Subsidiarie97%
EX21:9b0f005cb144EX21:9b0f005cb144Subsidiarie97%
EX21:9c91d4f3b8a6EX21:9c91d4f3b8a6Subsidiarie97%
EX21:9d777c7f741bEX21:9d777c7f741bSubsidiarie97%
EX21:9ea8d883ac3cEX21:9ea8d883ac3cSubsidiarie97%
EX21:a0a0b3eb4ba4EX21:a0a0b3eb4ba4Subsidiarie97%
EX21:a1c8ff6be479EX21:a1c8ff6be479Subsidiarie97%
EX21:a23e8d316869EX21:a23e8d316869Subsidiarie97%
EX21:a3b3891a47a2EX21:a3b3891a47a2Subsidiarie97%
EX21:a4564dcb742cEX21:a4564dcb742cSubsidiarie97%
EX21:a5fe3e7f5f40EX21:a5fe3e7f5f40Subsidiarie97%
EX21:a6cae4084c33EX21:a6cae4084c33Subsidiarie97%
EX21:a6cddad053adEX21:a6cddad053adSubsidiarie97%
EX21:a8658a36a978EX21:a8658a36a978Subsidiarie97%
EX21:a88ac7d0deaeEX21:a88ac7d0deaeSubsidiarie97%
EX21:a91994575c60EX21:a91994575c60Subsidiarie97%
EX21:ac5bdbe42647EX21:ac5bdbe42647Subsidiarie97%
EX21:ac78f90c7405EX21:ac78f90c7405Subsidiarie97%
EX21:ada0a2fd8bcbEX21:ada0a2fd8bcbSubsidiarie97%
EX21:adba428f2b0bEX21:adba428f2b0bSubsidiarie97%
EX21:ae072186c98aEX21:ae072186c98aSubsidiarie97%
EX21:af24635e9af2EX21:af24635e9af2Subsidiarie97%
EX21:af9b6fe9bdaaEX21:af9b6fe9bdaaSubsidiarie97%
EX21:b0b0ece213e1EX21:b0b0ece213e1Subsidiarie97%
EX21:b0e97e779ea6EX21:b0e97e779ea6Subsidiarie97%
EX21:b47e1535b549EX21:b47e1535b549Subsidiarie97%
EX21:b4bc118a9e63EX21:b4bc118a9e63Subsidiarie97%
EX21:b63f710f2c96EX21:b63f710f2c96Subsidiarie97%
EX21:b65291232a20EX21:b65291232a20Subsidiarie97%
EX21:b794745fd587EX21:b794745fd587Subsidiarie97%
EX21:b9f3e65380b5EX21:b9f3e65380b5Subsidiarie97%
EX21:bae09feee38eEX21:bae09feee38eSubsidiarie97%
EX21:bc118f6c8296EX21:bc118f6c8296Subsidiarie97%
EX21:bcaa95b59f69EX21:bcaa95b59f69Subsidiarie97%
EX21:bf82fc221799EX21:bf82fc221799Subsidiarie97%
EX21:c0d4def61f01EX21:c0d4def61f01Subsidiarie97%
EX21:c522a953f016EX21:c522a953f016Subsidiarie97%
EX21:c5a62131339eEX21:c5a62131339eSubsidiarie97%
EX21:c66f43a4d35bEX21:c66f43a4d35bSubsidiarie97%
EX21:cef4e2625e8aEX21:cef4e2625e8aSubsidiarie97%
EX21:d2dcfbc597ceEX21:d2dcfbc597ceSubsidiarie97%
EX21:d46cab975035EX21:d46cab975035Subsidiarie97%
EX21:d475113d4389EX21:d475113d4389Subsidiarie97%
EX21:d5f7b7cb2d87EX21:d5f7b7cb2d87Subsidiarie97%
EX21:d6576aed5553EX21:d6576aed5553Subsidiarie97%
EX21:d8ea9c28aae9EX21:d8ea9c28aae9Subsidiarie97%
EX21:d95f080a4b88EX21:d95f080a4b88Subsidiarie97%
EX21:dadc6fd06e0aEX21:dadc6fd06e0aSubsidiarie97%
EX21:dbca12241308EX21:dbca12241308Subsidiarie97%
EX21:dc5a374f9daeEX21:dc5a374f9daeSubsidiarie97%
EX21:ddcbcaa2771fEX21:ddcbcaa2771fSubsidiarie97%
EX21:e0d40f9afd16EX21:e0d40f9afd16Subsidiarie97%
EX21:e2791fb6598dEX21:e2791fb6598dSubsidiarie97%
EX21:e39697334733EX21:e39697334733Subsidiarie97%
EX21:e46a8f71b20eEX21:e46a8f71b20eSubsidiarie97%
EX21:e48195f1a635EX21:e48195f1a635Subsidiarie97%
EX21:e5932ab35b8fEX21:e5932ab35b8fSubsidiarie97%
EX21:e9926beede9fEX21:e9926beede9fSubsidiarie97%
EX21:e9df8efda72dEX21:e9df8efda72dSubsidiarie97%
EX21:ebd7d325b3c9EX21:ebd7d325b3c9Subsidiarie97%
EX21:ed1c44bea1e0EX21:ed1c44bea1e0Subsidiarie97%
EX21:edab0aed6da4EX21:edab0aed6da4Subsidiarie97%
EX21:eef1c7632247EX21:eef1c7632247Subsidiarie97%
EX21:ef8025747febEX21:ef8025747febSubsidiarie97%
EX21:f27175fb08ccEX21:f27175fb08ccSubsidiarie97%
EX21:f422e88fd259EX21:f422e88fd259Subsidiarie97%
EX21:f48a8ec93584EX21:f48a8ec93584Subsidiarie97%
EX21:f52ff25be3ebEX21:f52ff25be3ebSubsidiarie97%
EX21:f54ce778c1c6EX21:f54ce778c1c6Subsidiarie97%
EX21:f6232932685aEX21:f6232932685aSubsidiarie97%
EX21:f73f8035a2bfEX21:f73f8035a2bfSubsidiarie97%
EX21:f8fc5de31eceEX21:f8fc5de31eceSubsidiarie97%
EX21:fb57516421b6EX21:fb57516421b6Subsidiarie97%
EX21:fc205cd21159EX21:fc205cd21159Subsidiarie97%
EX21:fc228cb3b521EX21:fc228cb3b521Subsidiarie97%
EX21:fc867ab43a19EX21:fc867ab43a19Subsidiarie97%
EX21:fd6d385b7029EX21:fd6d385b7029Subsidiarie97%
EX21:fda1841a7a1dEX21:fda1841a7a1dSubsidiarie97%
EX21:fdf2e257b37dEX21:fdf2e257b37dSubsidiarie97%
Supply chain
Vendors → CL ↔ Partners → Customers · click any node to drill
1 mention in 10-K0 from corporate websites0 from news dispatches
Updated 2026-07-04Peer comparison
— missing data
Market position
Stress test
— missing data
Predictor forecast
Next quarternear-term
Earnings · next quarterconf 45 %
EPS
Consensus EPS
-0,09
Predicted surprise
+0,00
Beat probability
45 %
Analysts
8
Other metrics
Revenue
—
no estimate
Segment revenue
—
no estimate
Margin
—
no estimate
Segment margin
—
no estimate
as of 2026-05-04 · Earnings Surprise V1
Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
Full fiscal year~1 year ahead
Full fiscal year · our forecast vs guidance vs consensus
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,09 |
| Revenue | —no estimate | —no estimate | 618,5M USD |
| Operating income | —no estimate | —no estimate | 74,6M USD |
Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
Probabilistic model output — not investment advice. · generated 2026-08-04
Options
— missing data
Short squeeze
— missing data
Earnings-call key lines
— missing data
Consensus distribution
sell-side coverageRecommendation distribution8 analysts
Strong buy0
Buy8
Hold0
Sell0
Strong sell0
12-month price target$2,22 · Median $2,25
Low $2,00High $2,60
Operating income · consensus74,6M USD
EPS surprise
−2,9 %
reported vs consensus · miss
Revenue surprise
+6,0 %
reported vs consensus · beat
Estimate revisions
consensus EPS · 26-week trend— missing data
Sell-side observations
Low$2,00
Mean$2,22
Median$2,25
High$2,60
Spot$1,12
+98.2 %implied to mean12-month sell-side price targets · ▲ spot
Themes
— missing data
ESG
— missing data
Risk factors
Dilution riskLow
Liquidity riskMedium
Filing-based flags
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Op Margin-6,9 %Bottom quartile
Net Margin-20,6 %Bottom quartile
ROE-39,8 %Bottom quartile
Capex / Rev-5,8 %Bottom quartile
D/E1,32Bottom quartile
Cash Conv-0,27Bottom quartile
Corporate actions / M&A
M&A probabilityconf —
Probability
3 %
Base rate
3 %
Band
Low
180-day horizon · target 2027-01-20 · 1,0× base rate
No acquirer candidates identified by the signal model.
Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).
FX exposure
— missing data
Comparable transactions
— missing data
Derivatives & instruments
Derivative transactions
Net disposed 28 588 sh2 exercises · 9 grants10 insiders
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 424 @ $86,74grant · 2026-05-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 424 @ $86,74grant · 2026-05-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 020 @ $86,74grant · 2026-05-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 424 @ $86,74grant · 2026-05-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 424 @ $86,74grant · 2026-05-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 424 @ $86,74grant · 2026-05-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 424 @ $86,74grant · 2026-05-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 424 @ $86,74grant · 2026-05-11
- Director · Stock Option (Right to Buy) → Common StockAcquired 2 424 @ $86,74grant · 2026-05-11
- COO, Eur., APac, Afr Eur, Skin · Stock Option (Right to Buy) → Common StockDisposed 15 000 @ $76,41exercise · 2026-02-12
- COO, Eur., APac, Afr Eur, Skin · Stock Option (Right to Buy) → Common StockDisposed 35 000 @ $76,41exercise · 2026-02-11
Actions
Ask Handelsavisen
— missing data
Data sources
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
How metrics are computed
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
Source documents
- CL.CD Market data — financials · 2026-05-27
- Cresco Labs Inc Market data — analyst estimates · 2026-05-27
Ownership & reference
Top holders
- Institutional Investor · as of 2022-09-300,38 %$0M
- Investment Managers · as of 2026-03-310,33 %$3M
- Investment Managers · as of 2026-03-310,26 %$476M
- Institutional Investor · as of 2026-03-310,20 %$1 067M
- Investment Managers · as of 2026-03-310,18 %$248M
- Institutional Investor · as of 2026-03-310,14 %$420M
- Investment Managers · as of 2026-03-310,14 %$4 067M
- Investment Managers · as of 2024-06-300,14 %$5 979M
- Investment Managers · as of 2026-03-310,12 %$501M
- Investment Managers · as of 2026-03-310,12 %$1 965M
- Investment Managers · as of 2026-03-310,12 %$186M
- Funds · as of 2026-03-310,11 %$711M
- Investment Managers · as of 2026-03-310,11 %$1 780M
- Investment Managers · as of 2026-03-310,11 %$808M
- Institutional Investor · as of 2026-03-310,10 %$443M
- Investment Managers · as of 2026-03-310,10 %$197M
- Investment Managers · as of 2026-03-310,10 %$740M
- Investment Managers · as of 2025-12-310,10 %$6 634M
- Investment Managers · as of 2026-03-310,10 %$295M
- Investment Managers · as of 2026-03-310,09 %$442M
- Investment Managers · as of 2026-03-310,09 %$457M
- Investment Managers · as of 2024-12-310,08 %$270M
- Brokerage Firms · as of 2026-03-310,07 %$352M
- Investment Managers · as of 2026-03-310,07 %$393M
- Investment Managers · as of 2026-03-310,07 %$151M
- Investment Managers · as of 2026-03-310,07 %$436M
- Investment Managers · as of 2026-03-310,05 %$86M
- Investment Managers · as of 2026-03-310,04 %$76M
- Institutional Investor · as of 2026-03-310,04 %$768M
- Brokerage Firms · as of 2026-03-310,04 %$115M
- Investment Managers · as of 2026-03-310,02 %$66M
- Institutional Investor · as of 2026-03-310,01 %$18M
- Institutional Investor · as of 2026-03-310,01 %$11M
- Investment Managers · as of 2026-03-310,00 %$5M
- Investment Managers · as of 2026-03-310,00 %$0M
- Investment Managers · as of 2026-03-310,00 %$1M
- Investment Managers · as of 2026-03-310,00 %$1M
Insider activity
Net selling0 buys · 4 sellsnet -$5,7M17 insiders · last 365d
- Director · Common StockOther 293 @ $89,45$26K · 2026-07-01
- Director · Common StockOther 265 @ $89,45$24K · 2026-07-01
- Director · Common StockOther 209 @ $89,45$19K · 2026-07-01
- COO, Americas · Common StockOther 23 347 @ $90,66$2,1M · 2026-06-16
- EVP and Controller · Common StockSold 2 300 @ $88,44$203K · 2026-05-15
- Director · Common StockOther 2 075 · 2026-05-11
- Director · Common StockOther 2 075 · 2026-05-11
- Director · Common StockOther 2 075 · 2026-05-11
- Director · Common StockOther 1 383 · 2026-05-11
- Director · Common StockOther 2 075 · 2026-05-11
- Director · Common StockOther 2 075 · 2026-05-11
- Director · Common StockOther 1 556 · 2026-05-11
- Director · Common StockOther 2 075 · 2026-05-11
- Director · Common StockOther 2 075 · 2026-05-11
- Chief People Officer · Common StockSold 8 599 @ $87,41$752K · 2026-05-07
- Director · Common StockOther 294 @ $89,05$26K · 2026-04-01
- Director · Common StockOther 266 @ $89,05$24K · 2026-04-01
- Director · Common StockOther 210 @ $89,05$19K · 2026-04-01
- EVP and Controller · Common StockOther 6 268 · 2026-02-23
- Director, Chairman, President & CEO · Common StockOther 68 252 @ $97,10$6,6M · 2026-02-23
- Director, Chairman, President & CEO · Common StockOther 136 710 · 2026-02-23
- COO, Eur., APac, Afr Eur, Skin · Common StockOther 13 081 @ $97,10$1,3M · 2026-02-23
- COO, Eur., APac, Afr Eur, Skin · Common StockOther 25 742 · 2026-02-23
- Chief Financial Officer · Common StockOther 19 746 @ $97,10$1,9M · 2026-02-23
- Chief Financial Officer · Common StockOther 38 678 · 2026-02-23
Short positioning
16.7Mshares short-4.6% vs prior
3.86days to cover
35.9%short of daily vol
26.5Kfails-to-deliver
as of 2026-07-15 · short-interest report (free)
Index membership
S&P 500United States
Geographic breakdown
— missing data
Listings · one canonical issuer
all listings resolve to the canonical
CL.CDCanonical
— · USD
Intel & risk
peak dispatch · —
OSINT findings
Dilution riskLow
Liquidity riskMedium
Net cash is negative after subtracting total debt.
Relationship graph
This companySectorCustomersSubsidiaries
Evidence & claims
From filings & derived data- Operating income (YoY) (2025-12-31 vs 2024-12-31): -22.5%Derived (calculated)
- Net margin (FY 2025-12-31): 10.5%Derived (calculated)
- Gross margin (FY 2025-12-31): 60.1%Derived (calculated)
- Return on equity (FY 2025-12-31): 3,948.1%Derived (calculated)
- Return on assets (FY 2025-12-31): 13.1%Derived (calculated)
- Current ratio (FY 2025-12-31): 0.83xDerived (calculated)
- Debt-to-equity (FY 2025-12-31): 295.65xDerived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 17.5%Derived (calculated)
- Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 2.4%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -25.2%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -25.1%Derived (calculated)
- Gross profit (YoY) (2025-12-31 vs 2024-12-31): 0.7%Derived (calculated)
- Long-term debt (YoY) (2025-12-31 vs 2024-12-31): 11.9%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -26.2%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 2.2%Derived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 3.1%Derived (calculated)
- Revenue (YoY) (2025-12-31 vs 2024-12-31): 1.4%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -74.5%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 1.8%Derived (calculated)
- Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 3.0%Derived (calculated)
- Operating income (annual): USD 3.31BSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 3SEC XBRL filing
- Shares outstanding (annual): 801.24MSEC XBRL filing
- Current assets (annual): USD 5.71BSEC XBRL filing
Showing 24 of 60 surfaced claims.
Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.
The Thread
Everything we know, in order2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
2026-08-01 04:29 UTCFILINGMaterial 8-K
2026-07-31 00:00 UTCTRANSCRIPTEarnings call — Q3 2026
2026-07-01INSIDERBILBREY JOHN P transacted 265 sh — Director ~$24k
2026-07-01INSIDERNORRINGTON LORRIE M transacted 293 sh — Director ~$26k
2026-07-01INSIDERNewman Brian transacted 209 sh — Director ~$19k
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
2026-06-25 03:10 UTCHOLDERInstitutional holding changed
2026-06-25 03:10 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-23 03:11 UTCHOLDERInstitutional holding changed
2026-06-23 03:11 UTCHOLDER1 institutional position change flagged (1 major)
2026-06-16 00:00 UTCINSIDER1 insider transaction — 2026-06 · net sell $2.1M
2026-06-16 00:00 UTCINSIDER1 insider transaction — 2026-06 · net sell $2.1M
2026-06-16INSIDERGRANT SHANE transacted 23.3k sh — COO, Americas ~$2.12M
2026-05-15 00:00 UTCINSIDER20 insider transactions — 2026-05 · net sell $955k 9 derivative
2026-05-15 00:00 UTCINSIDER20 insider transactions — 2026-05 · net sell $955k 9 derivative
2026-05-15INSIDERMalcolm Gregory sold 2.3k sh — EVP and Controller ~$203k
2026-05-11INSIDERCAHILL JOHN T transacted 2.1k sh — Director
2026-05-11INSIDEREdwards Lisa transacted 2.1k sh — Director
2026-05-11INSIDERNewman Brian transacted 2.1k sh — Director
2026-05-11INSIDERBOERNER CHRISTOPHER S. transacted 1.4k sh — Director
2026-05-11INSIDERBILBREY JOHN P transacted 2.1k sh — Director
2026-05-11INSIDERHUNDMEJEAN MARTINA transacted 2.1k sh — Director
2026-05-11INSIDERHARRIS C MARTIN transacted 1.6k sh — Director
2026-05-11INSIDERNelson Kimberly A transacted 2.1k sh — Director
2026-05-11INSIDERNORRINGTON LORRIE M transacted 2.1k sh — Director
2026-05-11INSIDERHUNDMEJEAN MARTINA acquired 2.4k sh Stock Option (Right to Buy) — Director
2026-05-11INSIDERBILBREY JOHN P acquired 2.4k sh Stock Option (Right to Buy) — Director
2026-05-11INSIDERBOERNER CHRISTOPHER S. acquired 2.0k sh Stock Option (Right to Buy) — Director
2026-05-11INSIDERCAHILL JOHN T acquired 2.4k sh Stock Option (Right to Buy) — Director
2026-05-11INSIDEREdwards Lisa acquired 2.4k sh Stock Option (Right to Buy) — Director
2026-05-11INSIDERHARRIS C MARTIN acquired 2.4k sh Stock Option (Right to Buy) — Director
2026-05-11INSIDERNORRINGTON LORRIE M acquired 2.4k sh Stock Option (Right to Buy) — Director
2026-05-11INSIDERNelson Kimberly A acquired 2.4k sh Stock Option (Right to Buy) — Director
2026-05-11INSIDERNewman Brian acquired 2.4k sh Stock Option (Right to Buy) — Director
2026-05-07INSIDERMassey Sally sold 8.6k sh — Chief People Officer ~$752k
Showing the 40 most recent of 72 entries.
The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04
Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data
Premium coverage